HC Wainwright Weighs in on Bausch + Lomb Q1 Earnings

Bausch + Lomb Corporation (NYSE:BLCO) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Bausch + Lomb in a research report issued to clients and investors on Monday, February 23rd. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of $0.14 for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.74 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.27 EPS and FY2026 earnings at $0.78 EPS.

Bausch + Lomb (NYSE:BLCO) last posted its earnings results on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The business had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.38 billion. During the same quarter in the previous year, the firm earned $0.25 earnings per share. Bausch + Lomb’s quarterly revenue was up 9.8% compared to the same quarter last year.

BLCO has been the topic of several other research reports. The Goldman Sachs Group restated a “neutral” rating and set a $19.00 price objective on shares of Bausch + Lomb in a research report on Friday, January 9th. JPMorgan Chase & Co. upped their price objective on Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Stifel Nicolaus set a $16.00 price objective on Bausch + Lomb in a research report on Thursday. Royal Bank Of Canada boosted their target price on Bausch + Lomb from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 27th. Finally, Barclays increased their price target on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bausch + Lomb has a consensus rating of “Hold” and an average target price of $18.25.

Bausch + Lomb Price Performance

BLCO stock opened at $17.94 on Tuesday. The company’s 50 day moving average is $17.08 and its 200 day moving average is $15.90. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of -17.59, a price-to-earnings-growth ratio of 0.73 and a beta of 0.61. The company has a current ratio of 1.55, a quick ratio of 1.04 and a debt-to-equity ratio of 0.77. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $18.12.

Institutional Investors Weigh In On Bausch + Lomb

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its stake in shares of Bausch + Lomb by 428.7% in the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock worth $4,345,000 after acquiring an additional 242,993 shares during the last quarter. Woodline Partners LP grew its position in Bausch + Lomb by 0.5% during the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock valued at $4,536,000 after purchasing an additional 1,436 shares during the last quarter. Gruss & Co. LLC purchased a new stake in Bausch + Lomb during the 2nd quarter valued at about $130,000. Fountainhead AM LLC bought a new stake in Bausch + Lomb during the 2nd quarter valued at about $193,000. Finally, Kazazian Asset Management LLC purchased a new position in Bausch + Lomb in the second quarter worth about $722,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.